[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. https://doi.org/10.3322/caac.21654
|
[3]
|
Badiyan, S.N., Molitoris, J.K., Chuong, M.D., et al. (2017) The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Surgical Oncology Clinics of North America, 26, 431-453.
https://doi.org/10.1016/j.soc.2017.01.012
|
[4]
|
Maxwell, J.E. and Katz, M.H.G. (2021) Radiotherapy for Resectable and Borderline Resectable Pancreas Cancer: When and Why? Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract, 25, 843-848. https://doi.org/10.1007/s11605-020-04838-6
|
[5]
|
Manrai, M., Tilak, T., Dawra, S., et al. (2021) Current and Emerging Therapeutic Strategies in Pancreatic Cancer: Challenges and Opportunities. World Journal of Gastroenterology, 27, 6572-6589.
https://doi.org/10.3748/wjg.v27.i39.6572
|
[6]
|
Oettle, H., Neuhaus, P., Hochhaus, A., et al. (2013) Adjuvant Chemotherapy with Gemcitabine and Long-Term Outcomes among Patients with Resected Pancreatic Cancer: The CONKO-001 Randomized Trial. JAMA, 310, 1473-1481.
https://doi.org/10.1001/jama.2013.279201
|
[7]
|
Jin, Z., Hartgers, M.L., Sanhueza, C.T., et al. (2018) Prognostic Factors and Benefits of Adjuvant Therapy after Pancreatoduodenectomy for Ampullary Adenocarcinoma: Mayo Clinic Experience. European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 44, 677-683. https://doi.org/10.1016/j.ejso.2018.02.008
|
[8]
|
Khawaja, M.R., Kleyman, S., Yu, Z., et al. (2017) Adjuvant Gemcitabine and Gemcitabine-Based Chemoradiotherapy versus Gemcitabine Alone after Pancreatic Cancer Resection: The Indiana University Experience. American Journal of Clinical Oncology, 40, 42-46. https://doi.org/10.1097/COC.0000000000000115
|
[9]
|
Miccio, J.A., Talcott, W.J., Patel, T., et al. (2021) Margin Negative Resection and Pathologic Downstaging with Multiagent Chemotherapy with or without Radiotherapy in Patients with Localized Pancreas Cancer: A National Cancer Database Analysis. Clinical and Transla-tional Radiation Oncology, 27, 15-23.
https://doi.org/10.1016/j.ctro.2020.12.003
|
[10]
|
Van Laethem, J.L., Hammel, P., Mornex, F., et al. (2010) Adjuvant Gemcitabine Alone versus Gemcitabine-Based Chemoradiotherapy after Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD- 9203/GERCOR Phase II Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 4450-4456. https://doi.org/10.1200/JCO.2010.30.3446
|
[11]
|
Neoptolemos, J.P., Stocken, D.D., Friess, H., et al. (2004) A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. The New England Journal of Medicine, 350, 1200-1210.
https://doi.org/10.1056/NEJMoa032295
|
[12]
|
Rutter, C.E., Park, H.S., Corso, C.D., et al. (2015) Addition of Radi-otherapy to Adjuvant Chemotherapy Is Associated with Improved Overall Survival in Resected Pancreatic Adenocarci-noma: An Analysis of the National Cancer Data Base. Cancer, 121, 4141-4149. https://doi.org/10.1002/cncr.29652
|
[13]
|
Hsieh, M.C., Chang, W.W., Yu, H.H., et al. (2018) Adjuvant Radiothera-py and Chemotherapy Improve Survival in Patients with Pancreatic Adenocarcinoma Receiving Surgery: Adjuvant Chemotherapy Alone Is Insufficient in the Era of Intensity Modulation Radiation Therapy. Cancer Medicine, 7, 2328-2338. https://doi.org/10.1002/cam4.1479
|
[14]
|
You, M.S., Ryu, J.K., Huh, G., et al. (2020) Comparison of Efficacy between Adjuvant Chemotherapy and Chemoradiation Therapy for Pancreatic Cancer: AJCC Stage-Based Ap-proach. World Journal of Clinical Oncology, 11, 747-760.
https://doi.org/10.5306/wjco.v11.i9.747
|
[15]
|
Schmohl, K.A., Gupta, A., Grünwald, G.K., et al. (2017) Imaging and Targeted Therapy of Pancreatic Ductal Adenocarcinoma Using the Theranostic Sodium Iodide Symporter (NIS) Gene. Oncotarget, 8, 33393-33404.
https://doi.org/10.18632/oncotarget.16499
|
[16]
|
Fang, L.P., Xu, X.Y., Ji, Y., et al. (2018) Factors Influencing Sur-vival of Patients with Pancreatic Adenocarcinoma after Surgical Resection. Chinese Medical Journal, 98, 606-611.
|
[17]
|
Yamamoto, T., Yagi, S., Kinoshita, H., et al. (2015) Long-Term Survival after Resection of Pancreatic Cancer: A Single-Center Retrospective Analysis. World Journal of Gastroenterology, 21, 262-268.
https://doi.org/10.3748/wjg.v21.i1.262
|
[18]
|
Doi, R., Imamura, M., Hosotani, R., et al. (2008) Surgery versus Ra-diochemotherapy for Resectable Locally Invasive Pancreatic Cancer: Final Results of a Randomized Multi-Institutional Trial. Surgery Today, 38, 1021-1028.
https://doi.org/10.1007/s00595-007-3745-8
|
[19]
|
Liu, L., Xu, H., Wang, W., et al. (2015) A Preoperative Serum Signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL Indicates Poor Outcome to Pancreatectomy for Pancreatic Cancer. International Journal of Cancer, 136, 2216-2227.
https://doi.org/10.1002/ijc.29242
|
[20]
|
Smeenk, H.G., Van Eijck, C.H., Hop, W.C., et al. (2007) Long-Term Sur-vival and Metastatic Pattern of Pancreatic and Periampullary Cancer after Adjuvant Chemoradiation or Observation: Long-Term Results of EORTC Trial 40891. Annals of Surgery, 246, 734-740. https://doi.org/10.1097/SLA.0b013e318156eef3
|
[21]
|
Mirkin, K.A., Greenleaf, E.K., Hollenbeak, C.S., et al. (2016) Time to the Initiation of Adjuvant Chemotherapy Does Not Impact Survival in Patients with Resected Pancreatic Cancer. Cancer, 122, 2979-2987.
https://doi.org/10.1002/cncr.30163
|
[22]
|
Khorana, A.A., Mckernin, S.E., Berlin, J., et al. (2019) Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 37, 2082-2088. https://doi.org/10.1200/JCO.19.00946
|
[23]
|
Lee, K.H., Chie, E.K., Im, S.A., et al. (2021) Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. Cancer Research and Treatment, 53, 1096-1103. https://doi.org/10.4143/crt.2020.928
|
[24]
|
Yechieli, R.L., Robbins, J.R., Mahan, M., et al. (2017) Stereotactic Body Radiotherapy for Elderly Patients with Medically Inoperable Pancreatic Cancer. American Journal of Clinical Oncology, 40, 22-26.
https://doi.org/10.1097/COC.0000000000000090
|